CD5抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CD5 mouse mAb against K562 (1), Jurkat (2), Raji (3), and MOLT4 (4) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD5 mouse mAb (green) and negative control (red).    

  
  

CD5 antibodies target the CD5 glycoprotein, a cell surface receptor expressed primarily on T cells and a subset of B cells (B-1 cells). Discovered in the 1980s, CD5 plays roles in immune regulation, modulating T-cell receptor (TCR) signaling and B-cell activation. Structurally, it belongs to the scavenger receptor family and interacts with ligands like CD72 and CD166. influencing cell-cell interactions. In diagnostics, CD5 antibodies are key markers for identifying T-cell lymphomas and certain B-cell malignancies, notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), where aberrant CD5 expression aids classification.

Therapeutically, anti-CD5 antibodies have been explored for immune-mediated diseases and cancers. Early efforts focused on unconjugated antibodies to deplete malignant or autoreactive lymphocytes, but limited efficacy led to advanced strategies. Current approaches include antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies targeting CD5. For example, anti-CD5 ADCs aim to deliver toxins directly to CD5+ tumor cells, showing promise in preclinical models. Challenges include on-target/off-tumor effects due to CD5's presence on normal T cells, potentially causing immunosuppression. Additionally, CD5’s role in immune tolerance complicates therapeutic modulation.

Research continues to refine CD5-targeting agents, balancing efficacy and safety. Emerging insights into CD5’s dual roles—acting as both a co-stimulatory and inhibitory receptor—highlight its therapeutic complexity. Future directions may involve combination therapies or engineered antibodies with improved selectivity, advancing CD5-targeted interventions in oncology and autoimmunity.